Market view
Stock chart
Coverage
Analyses on Evogene (3)
- March 26, 2026March 26, 2026
- Follow-up
What Actually Reaches Evogene Shareholders: Non-Controlling Interests, Lavie Dividends, and the Biomica Path
After the Lavie sale and the BMC128 licensing deal, the core Evogene question is no longer only how much value remains inside the group, but how much of that value is actually owned and accessible at the parent. As of year-end 2025 the parent layer was still weak, Lavie had alre…
- Follow-up
Evogene After the Warrant Inducement: How Much Time Was Bought, and How Much Dilution Still Sits Above the Stock
The February 2026 warrant inducement bought Evogene a short liquidity bridge, but replaced it with a larger, cheaper and longer-lived dilution stack that still hangs over the stock and is tied directly to the Nasdaq bid-price problem.
Evogene 2025: ChemPass AI Is Now the Core, but the Thesis Still Runs Through Cash and Dilution
Evogene closed 2025 as a much more focused company around ChemPass AI, but the economics of the business still rely more on legacy activities, asset monetizations, and financing bridges than on the new core engine.
Same sector
